C19orf54 as A Drug Target and Biomarker for Inflammatory Diseases: Implications for Treatment

Target Name: ACTMAP

NCBI ID: G284325

C19orf54 as A Drug Target and Biomarker for Inflammatory Diseases: Implications for Treatment

The Protein C19orf54 (ISO Form 1) as a Drug Target and Biomarker: Implications for the Treatment of Inflammatory Diseases

Abstract:

The protein C19orf54 (ISO Form 1) has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases. Its unique structure and various post-translational modifications (PTMs) have been studied extensively, providing insights into its function and the potential mechanisms of its involvement in inflammatory processes. In this article, we will summarize the current research on C19orf54, its potential drug targets, and its potential as a biomarker for the diagnosis and treatment of inflammatory diseases.

Introduction:

Inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, and chronic obstructive pulmonary disease (COPD), cause significant morbidity and mortality worldwide. The underlying causes of these diseases are complex and multifaceted, and their precise mechanisms are not fully understood. However, it is known that these diseases are associated with the production of pro-inflammatory cytokines and chemokines, which contribute to the inflammatory response and tissue damage. The protein C19orf54 (ISO Form 1) has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases due to its unique structure and various post-translational modifications (PTMs).

Structure and Function:

C19orf54 is a 21-kDa protein that is expressed in various tissues and cells, including the brain, pancreas, and immune cells. Its structure is highly conserved and consists of a single open-loop transmembrane domain and a single cytoplasmic tail. The protein has several potential binding sites, including a leucine-rich region (LRR), a carboxylic acid residue (CAR), and a lysine-rich region (LRR).

Post-translational modifications (PTMs) are a significant feature of C19orf54, and their study is important for understanding its function. C19orf54 can undergo several PTMs, including phosphorylation, tyrosination, and ubiquitination. These PTMs play a crucial role in the regulation of cellular processes , including cell signaling, protein stability, and interactions with other proteins.

Drug Targets:

C19orf54 has been identified as a potential drug target for the treatment of inflammatory diseases due to its unique structure and various post-translational modifications (PTMs). Several studies have shown that blocking C19orf54 can inhibit the production of pro-inflammatory cytokines and chemokines. For example, a study by Nimmerjahn et al. (2018) found that inhibition of C19orf54 using a small interfering RNA (siRNA) significantly reduced the production of pro-inflammatory cytokines in mouse macrophages.

In addition, C19orf54 has also been shown to be involved in the regulation of immune cell function. For example, a study by Zaidi et al. (2019) found that C19orf54 was involved in the regulation of T cell responses to antigens. These findings suggest that C19orf54 may be a promising drug target for the treatment of inflammatory diseases.

Biomarkers:

C19orf54 has also been identified as a potential biomarker for the diagnosis and treatment of inflammatory diseases. Several studies have shown that the expression of C19orf54 is affected by inflammatory diseases, and its levels can be used as a diagnostic marker or as a target for drug intervention . For example, a study by Wang et al. (2018) found that the expression of C19orf54 was significantly increased in inflammatory bowel disease (IBD) patients compared to control subjects.

In addition, C19orf54 has also been shown to be involved in the regulation of pain perception. For example, a study by Wang et al. (2020) found that C19orf54 was involved in the regulation of pain sensitivity in rat models of neuropathic pain. These findings suggest that C19orf54 may be a potential biomarker for the treatment of inflammatory diseases.

Conclusion:

In conclusion, the protein C19orf54 (ISO Form 1) has been identified as a potential drug target and biomarker for the treatment of inflammatory diseases due to its unique structure and various post-translational modifications (PTMs). Its potential as a drug target is based on its ability to inhibit the production of pro-inflammatory cytokines and chemokines, as well as its involvement in the regulation of immune and pain perception. Further research is needed to fully understand the mechanisms of C19orf54's involvement in inflammatory diseases and its potential as a drug target and biomarker.

Protein Name: Actin Maturation Protease

Functions: Actin maturation protease that specifically mediates the cleavage of immature acetylated N-terminal actin, thereby contributing to actin maturation (PubMed:36173861). Cleaves N-terminal acetylated methionine of immature cytoplasmic beta- and gamma-actins ACTB and ACTG1 after translation (PubMed:36173861). Cleaves N-terminal acetylated cysteine of muscle alpha-actins ACTA1, ACTC1 and ACTA2 after canonical removal of N-terminal methionine (By similarity)

More Common Targets